Form 4: Evolent Health COO Emily Rafferty Reports Stock Transactions
SEC Form 4 Filing
Emily Rafferty, COO of Evolent Health, reports acquisition and disposal of Class A Common Stock due to vesting of restricted stock units and performance-based share units.
Summary
- Emily Rafferty, Chief Operating Officer of Evolent Health, filed a Form 4 detailing changes in her beneficial ownership of the company's Class A Common Stock.
- On March 1, 2025, 9,274 shares were disposed of to cover tax obligations upon vesting of restricted stock units at a price of $8.99.
- On March 3, 2025, Ms. Rafferty acquired 72,937 restricted stock units and 5,490 shares upon settlement of performance-based share units (PSUs).
- An additional 2,433 shares were disposed of on March 3, 2025, at $8.77 to cover tax obligations related to the PSU settlement.
- Following these transactions, Ms. Rafferty beneficially owns 130,128 shares of Class A Common Stock.
- The restricted stock units vest in three tranches: 34% on March 3, 2026, and 33% on March 3, 2027, and March 3, 2028.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs suggests the company met performance targets, which is a positive signal. The transactions themselves are routine and expected.
Positives
- The vesting of performance-based share units suggests that the company met certain performance metrics set by the Compensation Committee.
Future Outlook
The restricted stock units granted to Ms. Rafferty will vest over the next three years, indicating continued alignment with the company's long-term performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates that Evolent Health is using equity-based compensation to incentivize and retain its executives.
Comparison to Industry Standards
- Equity compensation is a common practice among publicly traded healthcare companies like Evolent Health to align executive interests with shareholder value.
- Companies such as UnitedHealth Group (UNH) and Humana (HUM) also utilize restricted stock units and performance-based awards as part of their executive compensation packages.
- The vesting schedules and performance metrics associated with these awards are typically designed to incentivize long-term growth and profitability.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
- Employees may view the vesting of PSUs as a positive sign of the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Date of performance-based share units (PSUs) awarded to the reporting person |
| 12/31/2024 | Conclusion of the performance period for the PSU award |
| 03/01/2025 | Date of Class A Common Stock disposal for tax obligations upon vesting of restricted stock units |
| 03/03/2025 | Date of Class A Common Stock acquisition of restricted stock units and settlement of performance-based share units (PSUs) |
| 03/03/2025 | Date of Class A Common Stock disposal for tax obligations upon settlement of performance-based share units (PSUs) |
| 03/03/2026 | Date of first vesting tranche (34%) of restricted stock units |
| 03/03/2027 | Date of second vesting tranche (33%) of restricted stock units |
| 03/03/2028 | Date of third vesting tranche (33%) of restricted stock units |
| 03/04/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.